Treatment of Fragile X Syndrome with Cannabidiol

A Case Series Study and Brief Review of the Literature

Nicole Tartaglia, Marcel Bonn-Miller, Randi J Hagerman

Research output: Contribution to journalReview article

Abstract

Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and to present a case series describing three patients with FXS who were treated with oral CBD-enriched (CBD+) solutions. We review recent animal and human studies of endocannabinoids in FXS and present the cases of one child and two adults with FXS who were treated with various oral botanical CBD+ solutions delivering doses of 32.0 to 63.9 mg daily. Multiple experimental and clinical models of FXS combine to highlight the therapeutic potential of CBD for management of FXS. All three patients described in the case series exhibited functional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory processing. Two of the described patients exhibited a reemergence of a number of FXS symptoms following cessation of CBD+ treatment (e.g., anxiety), which then improved again after reintroduction of CBD+ treatment. Findings highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalCannabis and Cannabinoid Research
Volume4
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Cannabidiol
Fragile X Syndrome
Endocannabinoids
Anxiety
Therapeutics
Sleep
Withholding Treatment
Intellectual Disability
Theoretical Models
Language
Clinical Trials

Keywords

  • cannabidiol
  • CBD
  • endocannabinoid system
  • fragile X syndrome
  • oral solution

ASJC Scopus subject areas

  • Pharmacology
  • Complementary and alternative medicine
  • Pharmacology (medical)

Cite this

Treatment of Fragile X Syndrome with Cannabidiol : A Case Series Study and Brief Review of the Literature. / Tartaglia, Nicole; Bonn-Miller, Marcel; Hagerman, Randi J.

In: Cannabis and Cannabinoid Research, Vol. 4, No. 1, 01.03.2019, p. 3-9.

Research output: Contribution to journalReview article

@article{0b8809a06346448a8371593cf3d0da52,
title = "Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature",
abstract = "Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and to present a case series describing three patients with FXS who were treated with oral CBD-enriched (CBD+) solutions. We review recent animal and human studies of endocannabinoids in FXS and present the cases of one child and two adults with FXS who were treated with various oral botanical CBD+ solutions delivering doses of 32.0 to 63.9 mg daily. Multiple experimental and clinical models of FXS combine to highlight the therapeutic potential of CBD for management of FXS. All three patients described in the case series exhibited functional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory processing. Two of the described patients exhibited a reemergence of a number of FXS symptoms following cessation of CBD+ treatment (e.g., anxiety), which then improved again after reintroduction of CBD+ treatment. Findings highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.",
keywords = "cannabidiol, CBD, endocannabinoid system, fragile X syndrome, oral solution",
author = "Nicole Tartaglia and Marcel Bonn-Miller and Hagerman, {Randi J}",
year = "2019",
month = "3",
day = "1",
doi = "10.1089/can.2018.0053",
language = "English (US)",
volume = "4",
pages = "3--9",
journal = "Cannabis and Cannabinoid Research",
issn = "2378-8763",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of Fragile X Syndrome with Cannabidiol

T2 - A Case Series Study and Brief Review of the Literature

AU - Tartaglia, Nicole

AU - Bonn-Miller, Marcel

AU - Hagerman, Randi J

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and to present a case series describing three patients with FXS who were treated with oral CBD-enriched (CBD+) solutions. We review recent animal and human studies of endocannabinoids in FXS and present the cases of one child and two adults with FXS who were treated with various oral botanical CBD+ solutions delivering doses of 32.0 to 63.9 mg daily. Multiple experimental and clinical models of FXS combine to highlight the therapeutic potential of CBD for management of FXS. All three patients described in the case series exhibited functional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory processing. Two of the described patients exhibited a reemergence of a number of FXS symptoms following cessation of CBD+ treatment (e.g., anxiety), which then improved again after reintroduction of CBD+ treatment. Findings highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.

AB - Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and to present a case series describing three patients with FXS who were treated with oral CBD-enriched (CBD+) solutions. We review recent animal and human studies of endocannabinoids in FXS and present the cases of one child and two adults with FXS who were treated with various oral botanical CBD+ solutions delivering doses of 32.0 to 63.9 mg daily. Multiple experimental and clinical models of FXS combine to highlight the therapeutic potential of CBD for management of FXS. All three patients described in the case series exhibited functional benefit following the use of oral CBD+ solutions, including noticeable reductions in social avoidance and anxiety, as well as improvements in sleep, feeding, motor coordination, language skills, anxiety, and sensory processing. Two of the described patients exhibited a reemergence of a number of FXS symptoms following cessation of CBD+ treatment (e.g., anxiety), which then improved again after reintroduction of CBD+ treatment. Findings highlight the importance of exploring the therapeutic potential of CBD within the context of rigorous clinical trials.

KW - cannabidiol

KW - CBD

KW - endocannabinoid system

KW - fragile X syndrome

KW - oral solution

UR - http://www.scopus.com/inward/record.url?scp=85066727208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066727208&partnerID=8YFLogxK

U2 - 10.1089/can.2018.0053

DO - 10.1089/can.2018.0053

M3 - Review article

VL - 4

SP - 3

EP - 9

JO - Cannabis and Cannabinoid Research

JF - Cannabis and Cannabinoid Research

SN - 2378-8763

IS - 1

ER -